Scopolamine, atropine, edaravone and dexmedetomidine (DrugBank: Atropine, Dexmedetomidine, Scopolamine, Edaravone)
12 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
2 | 筋萎縮性側索硬化症 | 1 |
4 | 原発性側索硬化症 | 0 |
6 | パーキンソン病 | 0 |
21 | ミトコンドリア病 | 0 |
34 | 神経線維腫症 | 0 |
46 | 悪性関節リウマチ | 0 |
70 | 広範脊柱管狭窄症 | 0 |
113 | 筋ジストロフィー | 0 |
212 | 三尖弁閉鎖症 | 0 |
215 | ファロー四徴症 | 0 |
226 | 間質性膀胱炎(ハンナ型) | 0 |
280 | 巨大動静脈奇形(頚部顔面又は四肢病変) | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04391361 (ClinicalTrials.gov) | November 1, 2020 | 13/5/2020 | The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS | The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis;Respiratory Function;Scopolamine | Drug: Scopolamine, atropine, edaravone and dexmedetomidine;Drug: Edaravone | Ruijin Hospital | NULL | Not yet recruiting | 30 Years | 65 Years | All | 30 | Phase 2 | China |